UCB supports new epilepsy patient centre in Beijing and partners with Chinese association to open more
Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent non-communicable diseases. In China, epilepsy constitutes a significant health challenge that affects nine million people with around 400,000 new cases diagnosed every year.
For further information, please contact:
In China during the mission: Didier Malherbe, VP Public Affairs, +32 475 86 79 91
For other inquiries: France Nivelle, VP Global Communications: +32 475 494 001
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. UCB employs more than 8500 people in about 40 countries. UCB entered China in 1996 and currently employs about 750 people all across China.
Asset Download
Stay up-to-date on the latest news and information from UCB